Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 468 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ACNE VULGARIS Clear all
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

NCT00441415
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene BPO
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Santa Monica, California • Fridley, Minnesota • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

NCT01830764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Red Light (PDT)
Drug
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

DMT210 Topical Gel in the Treatment of Acne Rosacea

NCT03003104
View directory record Official record
Conditions
Acne Rosacea
Interventions
DMT210 Topical Gel 5%, Vehicle Control
Drug · Other
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
San Diego, California • Miami, Florida • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate

NCT00635609
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline hyclate (Doryx), Doxycycline hyclate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Vista, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel

NCT03653403
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, Control Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Weekly Isotretinoin Therapy Study

NCT04594759
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 10, 2026, 9:53 PM EDT
Not yet recruiting Not applicable Interventional

Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

NCT06729450
View directory record Official record
Conditions
Acne Vulgaris on the Face
Interventions
DispersinB Acne Cleanser
Device
Lead sponsor
Kane Biotech Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 10, 2026, 9:53 PM EDT
Not listed Not applicable Interventional

Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars

NCT04807179
View directory record Official record
Conditions
Acne Scars
Interventions
Experimental: RF Device Arm
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Early Phase 1 Interventional

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

NCT03960268
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brodalumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of PRK 124 Lotion in Acne Rosacea

NCT00580723
View directory record Official record
Conditions
Acne Rosacea
Interventions
PRK 124
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Results available

Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study

NCT02147691
View directory record Official record
Conditions
Acne Rosacea
Interventions
Azelaic acid 15%, Brimonidine 0.33%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

NCT00660985
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 10, 2026, 9:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Photopneumatic System for the Treatment of Acne

NCT01257555
View directory record Official record
Conditions
Mild to Moderate Acne
Interventions
Photopneumatic therapy
Device
Lead sponsor
Solta Medical
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

NCT02965456
View directory record Official record
Conditions
Acne
Interventions
IDP 121 Lotion, IDP-121 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

NCT00714454
View directory record Official record
Conditions
Acne Vulgaris
Interventions
APS Topical Lotion, Placebo
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2008 · Synced Sep 10, 2026, 9:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

NCT03767400
View directory record Official record
Conditions
Skin Care
Interventions
Skin Imaging, Facial Cleanser
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Anifrolumab for Hidradenitis Suppurativa

NCT06374212
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions
Anifrolumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

NCT01182636
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, Differin®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Sep 10, 2026, 9:53 PM EDT
Withdrawn Phase 4 Interventional

A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris

NCT02647528
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Chromogenix Regenlite Transform Treatment, Chromogenix Regenlite Transform Placebo
Device
Lead sponsor
Sadick Research Group
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

NCT00991198
View directory record Official record
Conditions
Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
Interventions
Topical oxygen, placebo
Drug
Lead sponsor
Aria Aesthetics Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles

NCT04057768
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic, Wrinkle
Interventions
Venus Viva
Device
Lead sponsor
Venus Concept
Industry
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 10, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

NCT01119651
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Patch application in Challenge Phase)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 10, 2026, 9:53 PM EDT